European Commission Approves BAVENCIO® (avelumab) Plus Axitinib Combination for First-Line Treatment of Patients With Advanced Renal Cell Carcinoma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. ACN
9. USO
10. NVDA

Go back to European Commission Approves BAVENCIO® (avelumab) Plus Axitinib Combination for First-Line Treatment of Patients With Advanced Renal Cell Carcinoma
(AMEX: MKKGY) Delayed: 30.89 +0.33 (1.08%)
Previous Close $30.56    52 Week High $ 
Open $30.83    52 Week Low $ 
Day High $30.98    P/E N/A 
Day Low $30.68    EPS $ 
Volume 60,635       

Merck & Co. (NYSE: MRK) Delayed: 119.60 +4.12 (3.57%)
Previous Close $115.48    52 Week High $65.46 
Open $116.53    52 Week Low $47.97 
Day High $119.80    P/E 81.36 
Day Low $116.53    EPS $1.47 
Volume 11,893,949       

Pfizer Inc. (NYSE: PFE) Delayed: 24.72 -0.36 (1.44%)
Previous Close $25.08    52 Week High $37.39 
Open $24.99    52 Week Low $28.25 
Day High $25.24    P/E 14.98 
Day Low $24.69    EPS $1.65 
Volume 81,994,445